In conclusion, our findings reveal a major regulatory role for miRNAs in the emergence of reversible drug tolerance, and suggest that combining current targeted therapies with inhibitors of PLA2/PKCα and ROS accumulation could provide a treatment strategy to delay some types of drug resistance in human cancer. The gene discussed is PRKCA; the disease is cancer.